Skip to main content
ARTELO BIOSCIENCES, INC. logo

ARTELO BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · ARTL ISIN · US04301G7060 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2019-12-06 Board/Management Inform…
Country US United States of America
Listing US ARTL

About ARTELO BIOSCIENCES, INC.

https://artelobio.com/

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company's scientific approach is centered on modifying lipid-signaling pathways, particularly by modulating the endocannabinoid system. Its primary therapeutic focus is on developing improved treatments for patients with cancer and other serious diseases. Artelo is advancing a diverse portfolio of drug candidates through its development pipeline to address unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 2, 2019, reporting the appointment of a new director and the resignation of another director. The content focuses on changes in the company's board of directors, including biographical details and compensation arrangements for the new director. There are no financial statements or detailed financial performance data included. The primary subject is management and board changes, which aligns with the category for announcements of changes in the company's board or senior management. Therefore, the appropriate classification is 'Board/Management Information' (MANG). The document length (6522 characters) supports that this is a full report of the event, not just a brief announcement or a certification.
2019-12-06 English
FORM S-3 AMENDMENT NO. 1
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement Amendment filed with the SEC, specifically a Post-Effective Amendment No. 2 to a Form S-1 registration statement converted into a Form S-3. It includes a prospectus for the resale of shares by selling stockholders. The content focuses on securities registration, offering details, and compliance with the Securities Act of 1933. This type of filing is related to capital raising and securities offerings, which aligns with Capital/Financing Update filings. It is not an annual report, earnings release, or other financial report, nor is it a proxy, voting result, or management change announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2019-11-25 English
FORM S-3 AMENDMENT NO. 1
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Amendment No. 1 registration statement filed with the SEC by Artelo Biosciences, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the securities being registered, selling stockholders, and the prospectus summary. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report.
2019-11-25 English
FORM 10-K
Annual Report FY 2019
2019-11-25 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 14, 2019. It announces that the company's CEO will present at an investor event and references an updated slide presentation attached as Exhibit 99.1. The key content is the disclosure of an upcoming investor presentation and the inclusion of the presentation slides. There are no financial statements or detailed financial analysis within the text itself, only a reference to the presentation. The document length is 3129 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this type of document is best classified as an Investor Presentation (IP) since it includes the presentation material and focuses on investor communication rather than a regulatory filing or financial report.
2019-11-15 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-3. It specifically requests the withdrawal of an acceleration request for the effective date of the Registration Statement. The content is procedural and relates to a capital raising filing but does not contain financial data or the actual registration statement itself. The document length is short (1416 characters) and is a formal correspondence about a filing process rather than the filing itself. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and procedural communications with the SEC that do not fit other categories.
2019-11-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.